مركـز الكويـت لمكافحـة السرطـان
Kuwait Cancer Control Center

GEFitinib (Iressa®)

GEF-OOOOOO-DL-CN-TX

Ministry of Health

Name: **File #:** **Ht (cm):**
Nationality: **Civil ID:** **Wt (Kg):**
Gender/Age: **DOB:** **BSA (m²):**

Indication(s): First-line therapy of dvanced stage ALK positive lung adenocarcinoma with EGFR ex19del or exon 21 (L858R) mutation.

Central line: ☐ Available ☐ NA **Allergies:** ☐ NKA ☐ Yes, specify; _____

Standard Protocol:

DRUG	DOSE	ADMINISTRATION
GEFitinib	250 mg PO daily	To be given with or without food. Don't take a missed dose, if it is within 12 hrs of the next scheduled dose.
To be given continuously until disease progression or intolerable toxicity.		

Special instructions:
- Avoid grapefruit and grapefruit juice.
- Avoid Acid-suppressive drugs such as proton-pump inhibitors, H2 antagonists, and antacids.
- Avoid concomitant use with strong CYP3A4 inducers (Anticonvulsants). If used. concomitantly with potent CYP3A4 inducer, consider increasing gefitinib dosage to 500 mg daily in the absence of severe adverse effects.

Treatment Description:

Cycle	Date	GEFitinib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: ☐ None ☐ Hematological ☐ Non-Hematological

If yes; Did it indicate hospitalization? ☐ Yes ☐ No
Did it indicate chemo-delay for ≥ 7 days? ☐ Yes ☐ No
Did it indicate dose reduction? ☐ Yes ☐ No
Did it indicate G-CSF support? ☐ Yes ☐ No